QUEBEC CITY, February 1, 2005 – Canadian biotech company Advitech, Inc. (TSX-V: AVI) will present a scientific poster at the next Congress of the American Academy of Dermatology (AAD) to be held in New Orleans, February 18-23, 2005. The poster will show the findings of Advitech's recent open clinical study on XP-828L, its new oral treatment for psoriasis. More than 8,000 dermatologists and professionals from several countries participated in the last AAD congress. The event is also a major opportunity for leading dermatology companies to present their new products.
Leading dermatologist and psoriasis specialist Dr. Yves Poulin, who has participated as a principal investigator in more than 65 clinical studies, will attend this event and will present the study results.
"This is a great opportunity for us to participate in this unique annual event in dermatology,” stated Renaud Beauchesne, President and Chief Executive Officer of Advitech. “It will be an opportunity for us to receive direct input from leading clinicians and also to establish further contacts with potential partners for marketing this product in 2006”.
Advitech is now conducting a multi-centre, double-blind, placebo-controlled study with 84 patients with light to moderate plaque psoriasis. The results of this study are expected to be released at the end of the second quarter of 2005.
Advitech is a biotechnology company specializing in the development of biotechnology products from dairy proteins. Its key focus areas are in the fields of immunology and inflammatory processes. Its main platform, XP-828L, is a growth factor complex used as an oral treatment for psoriasis and other immune-mediated chronic inflammatory diseases. Advitech’s common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward- looking statements.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Michel Lamontagne, MBA
Vice President and Chief Financial Officer
(418) 686-7498 ext. 237
Vice-President, Sales and Marketing
(418) 686-7498 ext. 234